PDT Partners LLC Makes New $496,000 Investment in LeMaitre Vascular, Inc. $LMAT

Key Points

• PDT Partners LLC has acquired a new stake in LeMaitre Vascular, Inc., purchasing 5,913 shares valued at approximately $496,000.
• CEO George W. Lemaitre sold 100,000 shares for about $9.35 million, reducing his ownership in the company by 5.47%.
• LeMaitre Vascular reported a quarterly earnings of $0.60 EPS, exceeding expectations, along with a revenue increase of 15.0% year-over-year.

PDT Partners LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,913 shares of the medical instruments supplier's stock, valued at approximately $496,000.

A number of other large investors have also added to or reduced their stakes in the company. Royal Bank of Canada grew its holdings in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier's stock worth $9,579,000 after acquiring an additional 1,735 shares during the last quarter. Graham Capital Management L.P. grew its holdings in LeMaitre Vascular by 32.0% in the 1st quarter. Graham Capital Management L.P. now owns 7,247 shares of the medical instruments supplier's stock worth $608,000 after acquiring an additional 1,757 shares during the last quarter. Trexquant Investment LP grew its holdings in LeMaitre Vascular by 574.4% in the 1st quarter. Trexquant Investment LP now owns 40,907 shares of the medical instruments supplier's stock worth $3,432,000 after acquiring an additional 34,841 shares during the last quarter. Comerica Bank grew its holdings in LeMaitre Vascular by 5.2% in the 1st quarter. Comerica Bank now owns 144,038 shares of the medical instruments supplier's stock worth $12,085,000 after acquiring an additional 7,124 shares during the last quarter. Finally, Synovus Financial Corp grew its holdings in LeMaitre Vascular by 65.5% in the 1st quarter. Synovus Financial Corp now owns 9,837 shares of the medical instruments supplier's stock worth $825,000 after acquiring an additional 3,893 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 2.5%

NASDAQ LMAT traded down $2.37 during trading hours on Wednesday, reaching $93.26. 22,515 shares of the company's stock traded hands, compared to its average volume of 187,947. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The firm has a market cap of $2.11 billion, a PE ratio of 45.43, a PEG ratio of 2.50 and a beta of 0.79. The firm has a 50-day simple moving average of $89.16 and a 200 day simple moving average of $86.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same period last year, the company posted $0.52 EPS. LeMaitre Vascular's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is 38.83%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LMAT. Cantor Fitzgerald lifted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $97.60.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. This trade represents a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,815 shares of company stock valued at $11,280,206. Insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.